Loading…
← CockpitCompetitor Analysis › CAI Caris Life Sciences, Inc.Open in the cockpit ↗

Caris Life Sciences, Inc.CAICompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.

Momentum weak 34
Mkt cap
$5.59B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$115M
20-day average traded
Fwd P/E
79.4×
forward earnings
ROIC−WACC
+24.6 pp
WACC 8.4%
Hurdle
-43 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$19.50
1D-2.2%
1W-20.4%
1M-37.3%
3M-20.7%
6M+24.2%
YTD-27.7%
1Y-17.8%
ATR %10.7%
Beta1.90
52w lowhigh46.6% off high

What Caris Life Sciences does

Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.

Paid per test: Medicare and private insurers reimburse the lab for each tumor-sequencing report, while drug makers pay for access to its anonymised molecular and outcomes data and for companion-diagnostic development. Volumes depend on oncologists ordering the test and insurers agreeing to pay.

Products and services

  • Caris Molecular Intelligence (tumor profiling)
  • AI-driven biomarker discovery platform
  • Liquid biopsy testing

Customers

  • Oncologists
  • Cancer patients
  • Pharma companies (biomarker/companion diagnostics

Where it sits in the supply chain

  • Healthcare
  • Diagnostics/precision oncology
  • Molecular tumor profiling and AI-driven…

What could go right

  • Precision oncology test volume growth
  • Pharma biomarker partnership revenue

What could go wrong

  • Reimbursement/payer coverage risk
  • Intense competition in comprehensive genomic profiling

Moat: narrow (data, process know-how, scale). A large proprietary tumor molecular/clinical-outcomes database supports AI-driven biomarker discovery that is hard to replicate quickly.

Headquarters: Irving, Texas, US · Founded: 2008 · Employees: 1,846

Named competitors

Caris Life Sciences at a glance

Size Caris Life Sciences (CAI) is a United States Health Care company (Biotechnology) with a market value of $5.59B, the 1101st largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.50 on 18 Nov 2026.

Performance Over six months the shares gained 24.2%, against -1.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 61.5% over the last twelve months (peer median +3.6%); the operating margin is 13.3% (peer median -18.9%).

Valuation It trades at 79.4× forward earnings against a peer median of 47.3× (2nd most expensive of 7).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -43 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 24.6 points above its cost of capital (8.4% WACC).

Short interest Short interest is 4.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026CAI 122Peer median 100
Six months, rebased to 100: Caris Life Sciences against the median of its 20 peers (local-currency closes).

Caris Life Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$1.05B$812M$412M$306M
Revenue growth—+97%+35%—
Gross profit$724M$539M$179M$89.3M
EBITDA$162M$67.7M-$208M-$271M
Net income$96.1M-$68.1M-$282M-$341M
Free cash flow$21.2M$59.2M-$254M-$298M
Capital expenditure$55.0M$16.3M$8.44M$22.3M
Total debt$463M$428M$424M$217M

Quarterly statements and history in the cockpit →

Caris Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%ANTHEMSRRK300122ARWRKOD300347COGTDNTHADPT002252IMVTEWTX000661AXSMCGON1530603392TXG6696TWSTCAI6-month return →1-month return →
Up and to the right = strong over both horizons. Caris Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×100×ANTHEM300347002252000661AXSM1530CAIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Caris Life Sciences is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%ANTHEM300122300347000661TXGCAIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Caris Life Sciences is the large dot.

Caris Life Sciences competitors and peer comparison

Head to head with its named competitors (CAI vs RO.SW vs GH vs TEM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Caris Life Sciences CAI$5.59B+24%+61%13%79.4×18.2%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Guardant Health GH$19.6B+26%+42%-39%n/an/a
Tempus AI TEM$11.6B+39%+37%-18%n/an/a

How Caris Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Caris Life Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureCAIPeer medianRank in peer set
1-month return-37.3%+1.0%lowest of 21
6-month return+24.2%-1.4%7th highest of 21
Distance from 52-week high-46.6%-31.9%6th lowest of 21
Revenue growth (TTM)+61.5%+3.6%3rd highest of 15
Operating margin13.3%-18.9%4th highest of 16
Forward P/E79.4×47.3×2nd most expensive of 7
Growth the price implies (Req g, 7 yrs)18.2%32.4%2nd least demanding of 6
Growth delivered (Del g)+61.5%+16.4%highest of 6
Hurdle (Req g minus delivered)-43.3 pp+10.7 ppleast demanding of 6
ROIC minus cost of capital+24.6 pp-14.7 pp2nd highest of 13
EV / EBITDA32.6×n/a—
Net debt / EBITDA-1.9×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%79.4×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%64.3×36.9%+26.2%
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%n/an/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%n/a-6.5%-10.0%
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%n/an/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%97.0×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%n/an/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%n/an/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%12.8×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%30.3×32.4%+7.1%
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a

Questions

Who are Caris Life Sciences's main competitors?
Named competitors: Roche (Foundation Medicine) (RO.SW), Guardant Health (GH), Tempus AI (TEM), Exact Sciences (private or unlisted). The cockpit's measured peer set (industry) also includes Anthem Biosciences (ANTHEM.NS), Scholar Rock (SRRK), Chongqing Zhifei Biological Products (300122.SZ), Arrowhead Pharmaceuticals (ARWR), Kodiak Sciences (KOD), Hangzhou Tigermed Consulting (300347.SZ).
Is Caris Life Sciences expensive compared with its peers?
On forward p/e it trades at 79.4× against a peer median of 47.3×, 2nd most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -43 pp: the price already allows for a slowdown.
How has Caris Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +24.2% against -1.4% for the median peer; over one year -17.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.